Could breast cancer patients safely cut treatment time in half?

This study is testing whether patients with early-stage HER2-positive breast cancer who respond very well to initial treatment can safely receive only 6 months of targeted therapy instead of the standard 12 months. Researchers want to see if the shorter treatment works as well while reducing side effects, costs, and clinic visits. The trial involves 52 patients across multiple Canadian hospitals who have already shown no remaining cancer after their initial treatment.